113 related articles for article (PubMed ID: 8462126)
1. Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.
Dennis IF; Ramsay JR; Workman P; Bleehen NM
Cancer Chemother Pharmacol; 1993; 32(1):67-72. PubMed ID: 8462126
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of BW12C in combination with mitomycin C in patients with advanced gastrointestinal cancer.
Ramsay JR; Bleehen NM; Dennis I; Workman P; Ward R; Falk SJ; Bedford P; Wootton R; Nethersell AB
Int J Radiat Oncol Biol Phys; 1992; 22(4):721-5. PubMed ID: 1544845
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.
Propper DJ; Levitt NC; O'Byrne K; Braybrooke JP; Talbot DC; Ganesan TS; Thompson CH; Rajagopalan B; Littlewood TJ; Dixon RM; Harris AL
Br J Cancer; 2000 Jun; 82(11):1776-82. PubMed ID: 10839290
[TBL] [Abstract][Full Text] [Related]
4. BW12C perturbs normal and tumour tissue oxygenation and blood flow in man.
Falk SJ; Ramsay JR; Ward R; Miles K; Dixon AK; Bleehen NM
Radiother Oncol; 1994 Sep; 32(3):210-7. PubMed ID: 7816940
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies using BW12C: toxicity, haemoglobin modification and effects on the radiosensitivity of normal marrow and RIF-1 tumours in mice.
Honess DJ; Nethersell AB; Bleehen NM
Int J Radiat Biol; 1992 Jan; 61(1):83-94. PubMed ID: 1345934
[TBL] [Abstract][Full Text] [Related]
6. Protection of pig epidermis against radiation-induced damage by the infusion of BW12C.
van den Aardweg GJ; Hopewell JW; Adams GE; Barnes DW; Sansom JM; Stratford IJ; Nethersell AB
Int J Radiat Biol; 1991 Apr; 59(4):1039-51. PubMed ID: 1674270
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy.
Philip PA; Thompson CH; Carmichael J; Rea D; Mitchell K; Taylor DJ; Stuart NS; Dennis I; Rajagopalan B; Ganesan T
Cancer Res; 1993 Dec; 53(23):5649-53. PubMed ID: 8242619
[TBL] [Abstract][Full Text] [Related]
8. BW12C-induced changes in haemoglobin-oxygen affinity in mice and its influence on the radiation response of a C3H mouse mammary carcinoma.
Horsman MR; Overgaard J
Radiother Oncol; 1992 Sep; 25(1):43-8. PubMed ID: 1410589
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy.
Kuzuya T; Yamauchi M; Ito A; Hasegawa M; Hasegawa T; Nabeshima T
J Pharm Pharmacol; 1994 Aug; 46(8):685-9. PubMed ID: 7815285
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion.
Cerretani D; Nencini C; Urso R; Giorgi G; Marrelli D; De Stefano A; Pinto E; Cioppa T; Nastri G; Roviello F
J Chemother; 2005 Dec; 17(6):668-73. PubMed ID: 16433199
[TBL] [Abstract][Full Text] [Related]
11. BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice.
Honess DJ; Hu DE; Bleehen NM
Br J Cancer; 1991 Oct; 64(4):715-22. PubMed ID: 1911220
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of high-dose mitomycin C.
Schilcher RB; Young JD; Ratanatharathorn V; Karanes C; Baker LH
Cancer Chemother Pharmacol; 1984; 13(3):186-90. PubMed ID: 6386213
[TBL] [Abstract][Full Text] [Related]
13. The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve.
Fitzharris P; McLean AE; Sparks RG; Weatherley BC; White RD; Wootton R
Br J Clin Pharmacol; 1985 Apr; 19(4):471-81. PubMed ID: 3994894
[TBL] [Abstract][Full Text] [Related]
14. Effects of an increase in haemoglobin O2 affinity produced by BW12C on myocardial function in the erythrocyte-perfused rabbit heart in vitro and myocardial infarct size in the dog.
Allan G; Chapple DJ; Hughes B
Br J Pharmacol; 1986 Sep; 89(1):183-90. PubMed ID: 3801772
[TBL] [Abstract][Full Text] [Related]
15. A phase I-II study of continuous 5-day infusion mitomycin-C.
Yap HY; Valdivieso M; Blumenschein G; Hortobagyi G; Bedikian A
Am J Clin Oncol; 1983 Feb; 6(1):109-12. PubMed ID: 6404154
[TBL] [Abstract][Full Text] [Related]
16. The effect of BW12C on the radiosensitivity and necrosis of murine tissues and tumours.
Stevens G; Hill SA; Joiner MC; Joiner B; Johns H; Williams K; Denekamp J; Nethersell AB
Australas Radiol; 1994 Aug; 38(3):199-203. PubMed ID: 7945114
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
van Ruth S; Mathôt RA; Sparidans RW; Beijnen JH; Verwaal VJ; Zoetmulder FA
Clin Pharmacokinet; 2004; 43(2):131-43. PubMed ID: 14748621
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
van Hazel GA; Scott M; Rubin J; Moertel CG; Eagan RT; O'Connell MJ; Kovach JS
Cancer Treat Rep; 1983 Sep; 67(9):805-10. PubMed ID: 6411337
[TBL] [Abstract][Full Text] [Related]
19. Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma.
Erlichman C; Rauth AM; Battistella R; Fine S
Can J Physiol Pharmacol; 1987 Mar; 65(3):407-11. PubMed ID: 3107786
[TBL] [Abstract][Full Text] [Related]
20. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease.
Keidan AJ; Franklin IM; White RD; Joy M; Huehns ER; Stuart J
Lancet; 1986 Apr; 1(8485):831-4. PubMed ID: 2870317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
